RWM
TEVA icon

Ritholtz Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Ritholtz Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$694K Buy
20,490
+2,001
+11% +$66.6K 0.01% 739
2026
Q1 		$557K Buy
18,489
+7,574
+69% +$244K 0.01% 749
2025
Q4 		$341K Buy
10,915
+905
+9% +$22.3K 0.01% 844
2025
Q3 		$202K Sell
10,010
-498
-5% -$8.75K ﹤0.01% 975
2025
Q2 		$176K Sell
10,508
-11,283
-52% -$182K ﹤0.01% 927
2025
Q1 		$335K Sell
21,791
-13,163
-38% -$235K 0.01% 714
2024
Q4 		$770K Sell
34,954
-6,689
-16% -$122K 0.02% 447
2024
Q3 		$750K Buy
41,643
+30,374
+270% +$532K 0.02% 444
2024
Q2 		$183K Buy
+11,269
New +$174K 0.01% 775
2022
Q4 		– Sell
-10,560
Closed -$85K – 728
2022
Q3 		$85K Buy
+10,560
New +$93.4K ﹤0.01% 691
2018
Q2 		– Sell
-10,035
Closed -$171K – 120
2018
Q1 		$171K Sell
10,035
-1,915
-16% -$37.4K 0.05% 114
2017
Q4 		$226K Buy
+11,950
New +$180K 0.07% 105

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Ritholtz Wealth Management's TEVA Position: Q2 2026 in Review

Ritholtz Wealth Management increased its Teva Pharmaceuticals (TEVA) stake by 11% in Q2 2026, buying an estimated $66.6K and bringing the position to 20,490 shares worth $694K. The position accounts for 0.01% of the portfolio, ranked #739.

Ritholtz Wealth Management first reported a position in TEVA in Q4 2017 and has held it in 12 quarters since. The position peaked at $770K in Q4 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Ritholtz Wealth Management held 20,490 shares of Teva Pharmaceuticals worth $694K as of Q2 2026.
  • Ritholtz Wealth Management bought 2,001 Teva Pharmaceuticals shares in Q2 2026, an estimated $66.6K.
  • Teva Pharmaceuticals made up 0.01% of Ritholtz Wealth Management's portfolio in Q2 2026, its #739 holding.
  • Ritholtz Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 12 quarters since.
  • Ritholtz Wealth Management's Teva Pharmaceuticals position peaked at $770K in Q4 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.